Pertussis acellular vaccine - Pfizer

Drug Profile

Pertussis acellular vaccine - Pfizer

Latest Information Update: 13 Aug 2015

Price : $50

At a glance

  • Originator Baxter International
  • Developer Pfizer
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pertussis

Most Recent Events

  • 27 Jun 2000 North American Vaccine has been acquired by and merged into Baxter International
  • 06 Aug 1999 Preregistration for Pertussis in USA (Injection)
  • 06 Aug 1999 New profile, split from generic Pertussis acellular vaccine profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top